Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components.

Brooklyn Center for Health Disparities, SUNY Downstate Medical Center Brooklyn, NY 11203-2098, USA.
Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine (Impact Factor: 2.83). 07/2008; 4(3):261-72.
Source: PubMed

ABSTRACT Although obstructive sleep apnea and cardiovascular disease have common risk factors, epidemiologic studies show that sleep apnea increases risks for cardiovascular disease independently of individuals' demographic characteristics (i.e., age, sex, and race) or risk markers (i.e., smoking, alcohol, obesity, diabetes, dyslipidemia, atrial fibrillation, and hypertension). Individuals with severe sleep apnea are at increased risk for coronary artery disease, congestive heart failure, and stroke. The underlying mechanisms explaining associations between obstructive sleep apnea and cardiovascular disease are not entirely delineated. Several intermediary mechanisms might be involved including sustained sympathetic activation, intrathoracic pressure changes, and oxidative stress. Other abnormalities such as disorders in coagulation factors, endothelial damage, platelet activation, and increased inflammatory mediators might also play a role in the pathogenesis of cardiovascular disease. Linkage between obstructive sleep apnea and cardiovascular disease is corroborated by evidence that treatment of sleep apnea with continuous positive airway pressure reduces systolic blood pressure, improves left ventricular systolic function, and diminishes platelet activation. Several systematic studies are necessary to explicate complex associations between sleep apnea and cardiovascular disease, which may be compounded by the involvement of diseases comprising the metabolic syndrome (i.e., central obesity, hypertension, diabetes, and dyslipidemia). Large-scale, population-based studies testing causal models linking among sleep apnea, cardiovascular morbidity, and metabolic syndrome are needed.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stroke is one of the leading causes of mortality and disability in modern countries. Clinical mani-festation of stroke is rapidly developing loss of brain function(s) due to disturbance in the blood supply to the brain. This can be due to ischemia (lack of blood flow) caused by blockage (thrombosis, arterial embo-lism), or a hemorrhage (leakage of blood). Neuroplasticity (also known as cortical mapping) challenges the idea that brain functions are fixed in certain time. It refers to ability of the human brain to change as result of one's experience, that the brain is "plastic" and "malleable". The brain consists of nerve cells (neurons) and glial cells which are intercon-nected, and learning may happen through change in the strength of the connections, by adding or re-moving connections, or adding cells. This concept is captured in the aphorism, "neurons that fire together, wire together"/"neurons that fire apart, wire apart". Neuroplasticity can act through two possible mecha-nisms on stroke disability-prevention and treatment of neurological deficit (cognitive impairment). A sur-prising consequence of neuroplasticity is used in both cases-brain activity associated with a given function can move to a different location. This is fundamental issue that supports the scientific basis for treatment of acquired brain injury with goal directed experiential therapeutic programs in the context of rehabilitation approaches to functional consequences of the injury. Same mechanism are basis for brain "fitness" in order to prevent vascular dementia or to minimize stroke injury when it happens and to prepare better basis for further neurorehabilitation if it is needed. All of these methods include modulation of NMDA receptors, 5-lypoxigenase as a controlling enzyme and cox-2 en-zyme products which are involved also in pathomor-fological mechanisms of atherosclerosis and stroke as well as mood disorders (depression). Common risk factors for stroke have negative influence on neuro-plasticity. They are non modifiable risk factors: age, gender, race/ethnic, genotype, previous myocardial infarction, TIA or stroke and modifiable risk factors: diabetes, hyperlipidemia, arterial hypertension, atrial fibrillation, coronary and or peripheral artery disease, obesity, physical inactivity, stress, alcohol consump-tion, smoking. One of the important risk factor, but usually underrecognized is modern way of living, therefore we must learn how to recognize bad habits. We must learn how to cope stress with daily relax-ation techniques, a personal exercise program, perti-nent life style changes, a healthy diet, good sleep and appropriate nutritional habits. One of the important food ingredients which have strong impact on neu-roplasticity are flavonoids, ubiquitous polyphenols in plants and vegetables, have been identified as mainly by responsible for these actions. As key regulators of cell reactivity against oxidative aggressions, the fla-vonoid molecule can become an ideal template for compounds therapeutically active in stroke, dementia Some of the frequently used methods for enhanc-ing brain plasticity (prevention of cognitive impair-ment) are: • Music therapy: Auditory stimulation increases mean blood flow velocity (MBFV) in the middle cerebral artery (MCA) in healthy individuals. Bet-ter circulation enables better metabolism of the neurons and consequential neuroplasticity in both, healthy individuals and stroke patients.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study seeks to determine the risks for obstructive sleep apnea (OSA) and cardiometabolic disease (CMR) in elderly patients with mild-moderate abdominal aortic aneurysms (AAA).
    Sleep And Breathing 09/2014; · 2.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Resumen el síndrome metabólico es un conjunto de factores de riesgo de en-fermedad cardiovascular y se caracteriza por obesidad abdominal, hipertensión arterial, hipertrigliceridemia, resistencia a la insulina, hiperglucemia y disminución del colesterol hdL (lipoproteínas de alta densidad). Se ha propuesto que podría incluir al síndrome de apnea obstructiva del sueño (SAoS), y entonces se llamaría "síndrome Z" diagnóstico de síndrome metabólico el enfoque que más destaca es el Adult treatment Panel (AtP III), 2001. el SAoS, además de incrementar el riesgo de enfermedades cardiovasculares, reduce la calidad de vida, ya que favorece la aparición de accidentes de tráfico, laborales y domésticos, con lo que aumenta el riesgo de muerte. el tratamiento del SAoS con dispositivos de presión positiva continua en las vías respiratorias (cPAP) mejora el control glucémico y reduce la presión arterial y los síntomas relacionados con los trastornos respiratorios del sueño.

Full-text (2 Sources)

Available from
Nov 7, 2014